Plasma Cell-Free DNA and Caspase-3 Levels in Patients with Chronic Kidney Disease

被引:0
作者
Clementi, Anna [1 ,2 ]
Virzi, Grazia Maria [2 ,3 ]
Manani, Sabrina Milan [2 ,3 ]
de Cal, Massimo [2 ,3 ]
Battaglia, Giovanni Giorgio
Ronco, Claudio [3 ]
Zanella, Monica [2 ,3 ]
机构
[1] Santa Marta & Santa Venera Hosp, Dept Nephrol & Dialysis, I-95024 Acireale, Italy
[2] IRRIV Int Renal Res Inst, I-36100 Vicenza, Italy
[3] St Bortolo Hosp, Dept Nephrol Dialysis & Transplant, I-36100 Vicenza, Italy
关键词
cell free DNA; caspase-3; chronic kidney disease; HEMODIALYSIS; APOPTOSIS;
D O I
10.3390/jcm12175616
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cell-free plasma DNA (cfDNA) is circulating extracellular DNA arising from cell death mechanisms (apoptosis, necrosis, etc.). It is commonly existent in healthy individuals, but its ranks increase in diverse clinical circumstances, such as kidney disease, sepsis, myocardial infarction, trauma and cancer. In patients with advanced chronic kidney disease, cfDNA is connected to inflammation, and it has been associated with higher mortality. Caspase-3 plays a dominant role in apoptosis, a mechanism of programmed cell death involved in the pathogenesis and progression of chronic kidney disease (CKD). The aim of this pilot study was the evaluation of cfDNA levels and caspase-3 concentrations in patients with chronic kidney disease, in order to investigate the potential role of these molecules, deriving from inflammatory and apoptotic mechanisms, in the progression of renal damage. Methods: We compared cfDNA and caspase-3 levels in 25 CKD patients and in 10 healthy subjects, evaluating their levels based on CKD stage. We also explored correlations between cfDNA and caspase-3 levels in CKD patients and between cfDNA and caspase-3 levels and serum creatinine and urea in this population. Results: We observed that cfDNA and caspase-3 levels were higher in patients with CKD compared to healthy subjects, in particular in patients with advanced renal disease (CKD stage 5). A positive correlation between cfDNA and caspase-3 levels and between cfDNA and caspase-3 and creatinine and urea were also noticed. Conclusions: Patients with chronic kidney disease show higher levels of cfDNA and caspase-3 levels compared to the control group. Based on these preliminary results, we speculated that the worsening of renal damage and the increase in uremic toxin concentration could be associated with higher levels of cfDNA and caspase-3 levels, thus reflecting the potential role of inflammation and apoptosis in the progression of CKD. Future studies should focus on the validation of these promising preliminary results.
引用
收藏
页数:9
相关论文
共 50 条
[41]   Plasma cell-free DNA as an indicator of severity of injury in burn patients [J].
Chiu, TW ;
Young, R ;
Chan, LYS ;
Burd, A ;
Lo, DYM .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2006, 44 (01) :13-17
[42]   Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients [J].
Park, Jong-Lyul ;
Kim, Hyun Ja ;
Choi, Bo Youl ;
Lee, Han-Chul ;
Jang, Hay-Ran ;
Song, Kyu Sang ;
Noh, Seung-Moo ;
Kim, Seon-Young ;
Han, Dong Soo ;
Kim, Yong Sung .
ONCOLOGY LETTERS, 2012, 3 (04) :921-926
[43]   Serum cell-free DNA and progression of diabetic kidney disease: a prospective study [J].
Li, Xuan ;
Hu, RenZhi ;
Luo, Ting ;
Peng, Chuan ;
Gong, Lilin ;
Hu, Jinbo ;
Yang, Shumin ;
Li, Qifu .
BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (01)
[44]   Relationship of circulating cell-free DNA levels to cell-free fetal DNA levels, clinical characteristics and laboratory parameters in preeclampsia [J].
Lazar, Levente ;
Rigo, Janos, Jr. ;
Nagy, Balint ;
Balogh, Krisztian ;
Mako, Veronika ;
Cervenak, Laszlo ;
Mezes, Miklos ;
Prohaszka, Zoltan ;
Molvarec, Attila .
BMC MEDICAL GENETICS, 2009, 10
[45]   Cell-free DNA levels as a prognostic marker in acute myocardial infarction [J].
Antonatos, Dionisios ;
Patsilinakos, Sotirios ;
Spanodimos, Stavros ;
Korkonikitas, Panagiotis ;
Tsigas, D. .
CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM IV, 2006, 1075 :278-281
[46]   Cell-Free DNA As Peripheral Biomarker of Alzheimer's Disease [J].
Khemka, Sachi ;
Sehar, Ujala ;
Manna, Pulak R. ;
Kshirsagar, Sudhir ;
Reddy, P. Hemachandra .
AGING AND DISEASE, 2024, :787-803
[47]   Plasma α-oxoaldehyde levels in diabetic and nondiabetic chronic kidney disease patients [J].
Nakayama, Keisuke ;
Nakayama, Masaaki ;
Iwabuchi, Masashi ;
Terawaki, Hiroyuki ;
Sato, Toshinobu ;
Kohno, Masahiro ;
Ito, Sadayoshi .
AMERICAN JOURNAL OF NEPHROLOGY, 2008, 28 (06) :871-878
[48]   Prognostic Implication of Plasma Osteopontin Levels in Patients with Chronic Kidney Disease [J].
Barreto, Daniela V. ;
Lenglet, Aurelie ;
Liabeuf, Sophie ;
Kretschmer, Axel ;
Barreto, Fellype C. ;
Nollet, Aude ;
Slama, Michel ;
Choukroun, Gabriel ;
Brazier, Michel ;
Massy, Ziad .
NEPHRON CLINICAL PRACTICE, 2011, 117 (04) :C363-C372
[49]   Disease prediction by cell-free DNA methylation [J].
Feng, Hao ;
Jin, Peng ;
Wu, Hao .
BRIEFINGS IN BIOINFORMATICS, 2019, 20 (02) :585-597
[50]   Plasma Cell-Free DNA as a Novel Biomarker for the Diagnosis and Monitoring of Atherosclerosis [J].
Qian, Benheng ;
Li, Kexin ;
Lou, Xiaoying ;
Guo, Ye ;
Wang, Yidong ;
Wu, Lianpin ;
Zhang, Donghong .
CELLS, 2022, 11 (20)